337 related articles for article (PubMed ID: 33127761)
1. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response.
Biasci D; Smoragiewicz M; Connell CM; Wang Z; Gao Y; Thaventhiran JED; Basu B; Magiera L; Johnson TI; Bax L; Gopinathan A; Isherwood C; Gallagher FA; Pawula M; Hudecova I; Gale D; Rosenfeld N; Barmpounakis P; Popa EC; Brais R; Godfrey E; Mir F; Richards FM; Fearon DT; Janowitz T; Jodrell DI
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28960-28970. PubMed ID: 33127761
[TBL] [Abstract][Full Text] [Related]
2. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
3. AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells.
Fearon DT; Janowitz T
Br J Cancer; 2021 Jul; 125(2):149-151. PubMed ID: 33772153
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics.
Wei R; Li J; Lin W; Pang X; Yang H; Lai S; Wei X; Jiang X; Yuan Y; Yang R
Acta Biomater; 2024 Mar; 177():414-430. PubMed ID: 38360292
[TBL] [Abstract][Full Text] [Related]
5. Targeting CXCR4-dependent immunosuppressive Ly6C
Jung K; Heishi T; Incio J; Huang Y; Beech EY; Pinter M; Ho WW; Kawaguchi K; Rahbari NN; Chung E; Kim JK; Clark JW; Willett CG; Yun SH; Luster AD; Padera TP; Jain RK; Fukumura D
Proc Natl Acad Sci U S A; 2017 Sep; 114(39):10455-10460. PubMed ID: 28900008
[TBL] [Abstract][Full Text] [Related]
6. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.
Singh S; Srivastava SK; Bhardwaj A; Owen LB; Singh AP
Br J Cancer; 2010 Nov; 103(11):1671-9. PubMed ID: 21045835
[TBL] [Abstract][Full Text] [Related]
7. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
Feig C; Jones JO; Kraman M; Wells RJ; Deonarine A; Chan DS; Connell CM; Roberts EW; Zhao Q; Caballero OL; Teichmann SA; Janowitz T; Jodrell DI; Tuveson DA; Fearon DT
Proc Natl Acad Sci U S A; 2013 Dec; 110(50):20212-7. PubMed ID: 24277834
[TBL] [Abstract][Full Text] [Related]
8. The nanobody targeting PD-L1 and CXCR4 counteracts pancreatic stellate cell-mediated tumour progression by disrupting tumour microenvironment.
Li Y; Zheng Y; Xu S; Hu H; Peng L; Zhu J; Wu M
Int Immunopharmacol; 2024 May; 132():111944. PubMed ID: 38581990
[TBL] [Abstract][Full Text] [Related]
9. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.
Khan MA; Srivastava SK; Zubair H; Patel GK; Arora S; Khushman M; Carter JE; Gorman GS; Singh S; Singh AP
J Biol Chem; 2020 Jun; 295(25):8413-8424. PubMed ID: 32358063
[TBL] [Abstract][Full Text] [Related]
10. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
[TBL] [Abstract][Full Text] [Related]
11. A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis.
Morandi F; Ferretti E; Bocca P; Prigione I; Raffaghello L; Pistoia V
PLoS One; 2010 Jul; 5(7):e11763. PubMed ID: 20668702
[TBL] [Abstract][Full Text] [Related]
12. CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3.
Feng W; Huang W; Chen J; Qiao C; Liu D; Ji X; Xie M; Zhang T; Wang Y; Sun M; Tian D; Fan D; Nie Y; Wu K; Xia L
Theranostics; 2021; 11(6):2612-2633. PubMed ID: 33456563
[No Abstract] [Full Text] [Related]
13. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro.
Li JK; Yu L; Shen Y; Zhou LS; Wang YC; Zhang JH
World J Gastroenterol; 2008 Apr; 14(15):2308-13. PubMed ID: 18416455
[TBL] [Abstract][Full Text] [Related]
15. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer.
Xu Q; Wang Z; Chen X; Duan W; Lei J; Zong L; Li X; Sheng L; Ma J; Han L; Li W; Zhang L; Guo K; Ma Z; Wu Z; Wu E; Ma Q
Oncotarget; 2015 Mar; 6(7):4717-32. PubMed ID: 25605248
[TBL] [Abstract][Full Text] [Related]
16. CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients.
D'Alterio C; Giardino A; Scognamiglio G; Butturini G; Portella L; Guardascione G; Frigerio I; Montella M; Gobbo S; Martignoni G; Napolitano V; De Vita F; Tatangelo F; Franco R; Scala S
Cells; 2022 Oct; 11(21):. PubMed ID: 36359736
[TBL] [Abstract][Full Text] [Related]
17. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
Xue J; Li R; Gao D; Chen F; Xie H
Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
[TBL] [Abstract][Full Text] [Related]
18. Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer.
Yao Z; Qi C; Zhang F; Yao H; Wang C; Cao X; Zhao C; Wang Z; Qi M; Yao C; Wang X; Xia H
Acta Biomater; 2024 Jan; 173():365-377. PubMed ID: 37890815
[TBL] [Abstract][Full Text] [Related]
19. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
20. [Expression of CXCL12-CXCR4 and its association with angiogenesis in pancreatic cancer].
Niu ZX; Fei LM; Wang CL
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):286-7. PubMed ID: 19615285
[No Abstract] [Full Text] [Related]
[Next] [New Search]
